

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

1602 5 JUN 15 P2:14

June 14, 2005

**OVERNIGHT COURIER 6/14/05**

Division of Dockets Management  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**Withdrawal of Citizen Petition 2004P-0390/CP1**

Dear Sir or Madam:

The above-referenced petition was submitted to the FDA on August 31, 2004 under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30. The petition requested the Commissioner of the Food and Drug Administration to declare that the drug products Doxycycline Hyclate Tablets, 75 mg and 100 mg, are suitable for submission in an abbreviated new drug application (ANDA). At this time, Lachman Consultant Services, Inc. requests that this petition be withdrawn.

Sincerely,



Robert W. Pollock, Vice President  
Lachman Consultant Services, Inc.  
1600 Stewart Avenue  
Westbury, NY 11590

RWP/pk

cc: Emily Thakur (Office of Generic Drugs)

P04P5165

2004P-0390

WDL 1